Search Results
Apr 29, 2026, 18:03 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Apr 29, 2026, 17:50 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Apr 29, 2026, 13:45 ET ABC Impact công bố Báo cáo tác động năm 2025
trên cả Quỹ I và II. Danh mục đầu tư trải rộng gồm các nền tảng nhà cung cấp dịch vụ tích hợp, mạng lưới lọc máu, dược phẩm Hệ thần kinh trung ương (CNS) và công nghệ y tế – phản ánh nỗ lực có tính toán nhằm xây dựng sự hiện diện trên nhiều giai đoạn khác nhau của chuỗi cung cấp dịch vụ chăm
More news about: ABC Impact
Apr 29, 2026, 12:24 ET The Multiple Sclerosis Association of America Hosts 12th Improving Lives Benefit in Support of the MS Community
SclerosisMultiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America
Apr 29, 2026, 06:22 ET ABC Impact Luncurkan "2025 Impact Review"
menyoroti langkah ABC Impact dalam memperkuat fokus di sektor layanan kesehatan yang mencakup platform kesehatan terintegrasi, jaringan dialisis, obat CNS (gangguan sistem saraf pusat), hingga teknologi medis—mencerminkan pendekatan menyeluruh di sepanjang rantai nilai layanan kesehatan.Di Filipina,
More news about: ABC Impact
Apr 28, 2026, 16:05 ET PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
Huntingtin (HTT) lowering at 12 weeks and safety events. Secondary endpoints included 12-month blood HTT levels, and other blood-and central nervous system (CNS) biomarkers as well as changes in Composite Unified Huntington's Disease Rating Scale (cUHDRS).Following 12 months, patients were eligible to
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 09:28 ET PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
Huntingtin (HTT) lowering at 12 weeks and safety events. Secondary endpoints included 12-month blood HTT levels, and other blood-and central nervous system (CNS) biomarkers as well as changes in Composite Unified Huntington's Disease Rating Scale (cUHDRS).Following 12 months, patients were eligible to
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 08:00 ET Aligning Science Across Parkinson's and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments
is deeply rooted in the belief that we can accelerate advances by fostering a collaborative and open approach to research. It is an initiative of the CNS Quest, a program of the Sergey Brin Family Foundation and Catalyst4 to accelerate discoveries and improve daily life for people impacted by Parkinson's
More news about: Aligning Science Across Parkinson's
Apr 27, 2026, 16:30 ET Apertura Gene Therapy and Scientists from the Broad Institute to Share Data on TfR1 CapX™, a Novel Capsid Targeting the Central Nervous System (CNS), at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
"We are excited to share our findings and help foster a community of open sharing amongst groups using TfR1 CapX to develop gene therapies for the CNS." Apertura Presentation DetailsTitle: Defining pharmacologically relevant animal models for characterizing human transferrin
More news about: Apertura Gene Therapy
Apr 27, 2026, 09:00 ET Cohen & Steers Announces the Retirement of Francis C. Poli, General Counsel & Corporate Secretary
NEW YORK, April 27, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced that Francis C. Poli, Executive Vice President, General Counsel and Corporate Secretary, will retire in the first quarter of 2027 after
More news about: Cohen & Steers, Inc.
Apr 27, 2026, 08:00 ET Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) cancers, updated on April 24, 2026. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1-positive (ROS1+) non-small
More news about: Nuvation Bio Inc.
Apr 27, 2026, 08:00 ET Avista Therapeutics Announces Presentations at Upcoming Medical Meetings
through AI-driven innovation. Avista is dedicated to providing meaningful therapies to patients and addressing devastating diseases in the retina and CNS. Avista is a UPMC Enterprises portfolio company based in Pittsburgh, PA.
More news about: Avista Therapeutics
Apr 24, 2026, 09:00 ET Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
Economy."Based on Chemistry42 and its 40+ models, Insilico's team screened 90 AI-powered novel candidates, considering multiple parameters with a focus on CNS-specific traits, completing the lead discovery phase in just six months.ABU DHABI, UAE, April
More news about: Insilico Medicine
Apr 24, 2026, 04:29 ET Kebangkitan Desa Pegunungan: "Homestay Economy" di Guizhou Jadi Angin Segar bagi Desa-Desa Etnik
BIJIE, Tiongkok, 24 April 2026 /PRNewswire/ -- Artikel berita dari CNS: Di pelosok pegunungan Guizhou di Tiongkok barat daya, desa-desa etnis Miao dan Dong kini bertransformasi dari permukiman tradisional menjadi destinasi wisata yang semakin menarik bagi wisatawan.Sebagai salah satu
More news about: CNS
Apr 23, 2026, 09:04 ET Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla USA Inc.
Apr 23, 2026, 09:00 ET NEURELIS HELPS SUPPORT NATIONAL NETWORK OF EPILEPSY AWARENESS AND SUPPORT AT FIRST EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT WALT DISNEY WORLD
Hypersensitivity to diazepamAcute narrow-angle glaucomaCentral Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Apr 23, 2026, 03:00 ET MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
otherwise not have ready access to such therapies. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. Additional information can
More news about: Specialised Therapeutics
Apr 22, 2026, 23:37 ET AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
have limited CNS exposure.Preclinical studies showed that ABK-CDK4:High selectivity: Over 50-fold selectivity for CDK4 versus CDK6, potentially reducing CDK6-related toxicity.CNS penetration: Favorable CNS exposure (Kpuu
More news about: Abbisko Therapeutics
Apr 22, 2026, 17:13 ET Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Duncan. "Having covered a large number of Neuro-Innovator companies during my sell-side career, I see Vanda having a long history of innovation within CNS disorders, and it has served well patients in need. That said, with recent approvals of NEREUS™ and BYSANTI™, previous label expansion for Fanapt®
More news about: Vanda Pharmaceuticals Inc.
Apr 22, 2026, 08:30 ET Neuroscience Drug Development: How Novel Applications of AI Could Meaningfully Disrupt Traditional Development Strategies, Upcoming Webinar Hosted by Xtalks
In this free webinar, see how AI can deliver practical value across the CNS trial journey today in eCOA, imaging and rater training. Attendees will gain insight into the role for AI-supported vocal biomarkers to augment and accelerate psychiatric drug development. The featured speakers will discuss
More news about: Xtalks
Apr 22, 2026, 02:13 ET ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'
partners worldwide to apply our ELP and LMT15 platforms to a wide range of CNS and metabolic disease candidates."Earlier this year, ImmunoForge filed for a patent for LMT15 and is now initiating full-scale development for its CNS pipeline.Beyond its platform technologies, ImmunoForge continues
More news about: ImmunoForge Co., Ltd.
Apr 21, 2026, 22:10 ET Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
technology, which conjugates the siRNA duplex to an accessory oligonucleotide (ACO). This innovative architecture enables widespread central nervous system (CNS) distribution and exceptionally durable target engagement following a single intrathecal (IT) injection, potentially allowing for significantly extended
More news about: Ractigen Therapeutics
Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./
of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About IBTROZIIBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough
More news about: Nuvation Bio Inc.
Apr 21, 2026, 10:32 ET Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Apr 21, 2026, 08:04 ET Bắc cầu qua vực thẳm: Cách Quý Châu, Trung Quốc đang tái định hình địa hình miền núi
QUÝ DƯƠNG, Trung Quốc, ngày 21 tháng 4 năm 2026 /PRNewswire/ -- Theo bản tin từ CNS:Giữa những dãy núi đá vôi ở tây nam Trung Quốc, hàng loạt siêu dự án cầu — vươn mình qua các vực sâu và xuyên qua tầng mây — đang làm thay đổi căn bản cả diện mạo địa lý lẫn tiến trình phát triển của tỉnh
More news about: CNS